Opendata, web and dolomites

BIOCAPAN SIGNED

BIOactive implantable CApsule for PANcreatic islets immunosuppression free therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOCAPAN project word cloud

Explore the words cloud of the BIOCAPAN project. It provides you a very rough idea of what is the project "BIOCAPAN" about.

clinical    survival    protocol    maximum    implanting    islet    unprotected    applicability    reduces    full    microencapsulation    cells    reproducible    glycaemia    protect    pancreatic    standardized    benefit    option    reductions    limits    reactions    encapsulated    six    tremendously    frequent    shown    provisions    adverse    maximize    prevention    islets    refresher    allogeneic    modulation    platform    harvested    microenvironment    immune    pericapsular    life    lifelong    injections    start    medicinal    microfluidic    immunosuppressants    glycaemic    complications    trials    constant    treatment    preclinical    quality    fibrotic    grade    bioactive    implantations    protecting    matrix    diabetes    gmp    extend    injection    innovative    transplantation    overgrowth    insulin    freshly    encapsulation    administration    self    grafts    therapy    microcapsule    reconstruction    validation    implantation    situ    free    accordance    extracellular    issue    therapeutic    complete    strategies    patients    oxygenation    mellitus    regulation    biocapan    experts    tremendous   

Project "BIOCAPAN" data sheet

The following table provides information about the project.

Coordinator
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

Organization address
address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015
website: www.cea.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.biocapan.eu
 Total cost 7˙998˙875 €
 EC max contribution 7˙998˙875 € (100%)
 Programme 1. H2020-EU.2.1.3.1. (Cross-cutting and enabling materials technologies)
 Code Call H2020-NMP-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) coordinator 1˙988˙570.00
2    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 1˙364˙915.00
3    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 1˙194˙291.00
4    NANOIMMUNOTECH SL ES (VIGO PONTEVEDRA) participant 853˙225.00
5    UNIVERSITE GRENOBLE ALPES FR (GRENOBLE) participant 783˙878.00
6    WAKE FOREST UNIVERSITY HEALTH SCIENCES US (WINSTON SALEM NC) participant 764˙918.00
7    ETABLISSEMENT FRANCAIS DU SANG FR (LA PLAINE SAINT DENIS) participant 652˙940.00
8    FMC BIOPOLYMER AS NO (SANDVIKA) participant 236˙861.00
9    EUROPEAN RESEARCH SERVICES GMBH DE (MUENSTER) participant 159˙275.00
10    UNIVERSITE GRENOBLE ALPES FR (SAINT MARTIN D'HERES) participant 0.00
11    UNIVERSITE JOSEPH FOURIER GRENOBLE 1 FR (GRENOBLE) participant 0.00

Map

 Project objective

The key therapeutic issue in diabetes mellitus type I and II is glycaemic control. Reductions of constant self-control, of insulin injections, and of long-term complications would have tremendous benefit for quality of life. The best therapy option is the transplantation of allogeneic islet cells, but the current state of the art limits the applicability of this approach. Implanting unprotected grafts requires lifelong administration of immunosuppressants, and protecting the cells against adverse immune reactions by current encapsulation strategies reduces their functionality and survival to an extend that makes frequent ‘refresher’ implantations necessary. Currently, a maximum of 2 years glycaemia regulation has been shown for the encapsulated approach.

In BIOCAPAN, bringing experts from different fields all together, we aim at developing an innovative treatment, based on the implantation of allogeneic islet cells that are embedded in a complex microcapsule. We will design a GMP-grade bioactive microcapsule that will maximize the long-term functionality and survival of pancreatic islets by prevention of pericapsular fibrotic overgrowth, in situ oxygenation, innovative extracellular matrix microenvironment reconstruction and immune-system modulation. We will establish a GMP-grade microfluidic microencapsulation platform to protect freshly harvested islets quickly in a standardized and reproducible way.

We aim for full preclinical validation and we will establish a complete protocol in accordance with the provisions of the Advanced Therapy Medicinal Products Regulation, in order to start clinical trials within one year after the end of the project. We aim for 5-years insulin injection free treatment, without immunosuppressants, which would tremendously benefit diabetes mellitus patients who require insulin (all Type I and about one in six Type II Diabetes Mellitus patients).

 Deliverables

List of deliverables.
Demonstrator Demonstrators, pilots, prototypes 2020-04-01 18:38:32
Website and flyer Websites, patent fillings, videos etc. 2020-04-01 18:38:32

Take a look to the deliverables list in detail:  detailed list of BIOCAPAN deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Camille Laporte, Emily Tubbs, Justine Cristante, Anne-Sophie Gauchez, Sandra Pesenti, Frédéric Lamarche, Cécile Cottet-Rousselle, Catherine Garrel, Anaick Moisan, Jean-Marc Moulis, Eric Fontaine, Pierre-Yves Benhamou, Sandrine Lablanche
Human mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin
published pages: , ISSN: 1757-6512, DOI: 10.1186/s13287-019-1190-4
Stem Cell Research & Therapy 10/1 2020-04-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOCAPAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOCAPAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.1.)

ELASTISLET (2015)

Tailored Elastin-like Recombinamers as Advanced Systems for Cell Therapies in Diabetes Mellitus: a Synthetic Biology Approach towards a Bioeffective and Immunoisolated Biosimilar Islet/Cell Niche

Read More  

MOSTOPHOS (2015)

Modelling stability of organic phosphorescent light-emitting diodes

Read More  

EXTMOS (2015)

EXTended Model of Organic Semiconductors

Read More